Recombinant Erythropoietin for Chemotherapy-Related Anaemia
The results highlight a societal view that the severity of chemotherapy- related anaemia will significantly affect cancer patients’ HR-QOL. The DCE survey shows that the public value favourably the attributes of treatment with recombinant erythropoietin, and indicates a likely patient preference for treatment with recombinant erythropoietin over blood transfusion Copyright Adis Data Information BV 2007
Volume (Year): 25 (2007)
Issue (Month): 3 (March)
|Contact details of provider:|| Web page: http://www.springer.com/economics/journal/40273|
|Order Information:||Web: http://link.springer.de/orders.htm|
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Han Bleichrodt & José Luis Pinto & José María Abellán-Perpiñán, 2003.
"A consistency test of the time trade-off,"
Working Papers, Research Center on Health and Economics
676, Department of Economics and Business, Universitat Pompeu Fabra.
- McIntosh, E. & Ryan, M., 2002. "Using discrete choice experiments to derive welfare estimates for the provision of elective surgery: Implications of discontinuous preferences," Journal of Economic Psychology, Elsevier, vol. 23(3), pages 367-382, June.
- Roe, Brian & Boyle, Kevin J. & Teisl, Mario F., 1996. "Using Conjoint Analysis to Derive Estimates of Compensating Variation," Journal of Environmental Economics and Management, Elsevier, vol. 31(2), pages 145-159, September.
When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:25:y:2007:i:3:p:223-237. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Sonal Shukla)or (Christopher F Baum)
If references are entirely missing, you can add them using this form.